Immunex Novantrone Proposed Labeling For MS Indication
"Novantrone is indicated for the treatment of patients with secondary progressive multiple sclerosis, including progressive relapsing disease. Novantrone has been shown to slow the progression of physical disability and neurologic impairment, reduce the frequency of clinical relapse, increase the time to the first treated relapse, and reduce the number of hospitalizations.
You may also be interested in...
Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011